Min Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Min Chen has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Kaijun Wang
Department of Ophthalmology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
17 shared publications Xin Liu
Eye Center of Second Affiliated Hospital, School of Medicine, Zhejiang University, Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Hangzhou, China
11 shared publicationsNaiji Yu
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China
10 shared publicationsQi Zhang
Eye Center of Second Affiliated Hospital, School of Medicine, Zhejiang University, Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Hangzhou, China
9 shared publicationsQiyu Qin
Eye Center of Second Affiliated Hospital, School of Medicine, Zhejiang University, Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Hangzhou, China
7 shared publicationsChengshou Zhang
Eye Center of Second Affiliated Hospital, School of Medicine, Zhejiang University, Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Hangzhou, China
6 shared publications
Latest Publications
- Open Access
- 25 August 2026
- Published by Springer Nature in Journal of Translational Medicine
The expression level of PGAM5 regulates acute ocular hypertension-induced retinal ganglion cell injury
- 25 August 2026
- Published by Springer Nature in Journal of Translational Medicine
Open AccessThe expression level of PGAM5 regulates acute ocular hypertension-induced retinal ganglion cell injury
- Open Access
- 1 February 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-11
Implementation and Clinical Application of 24-Hour Intraocular Pressure Monitoring in China: A Nationwide Survey
To evaluate the nationwide implementation and clinical application of 24-hour intraocular pressure (IOP) monitoring in China. A nationwide descriptive cross-sectional study was conducted from September 2024 to March 2025. Two structured questionnaires were distributed to 467 hospitals across China (400 valid responses) and 170 patients recruited from our institution who were undergoing 24-hour IOP monitoring for the first time. Collected data included implementation rates, tonometer types, measurement protocols, examiner consistency, and patient-reported perceptions. Among the 400 responding hospitals, 261 (65.3%) had implemented 24-hour IOP monitoring; however, 85.1% managed fewer than 20 patients per month. The most common measurement frequencies within a 24-hour period were 12 (37.2%), 6 (32.6%), and 7 times (27.2%), respectively. Non-contact tonometer (NCT) was the predominant device for both daytime (67.8%) and nighttime (64.6%) measurements. Among the 175 hospitals performing nocturnal measurements, only 7.4% employed supine positioning. In 65.5% of institutions, 24-hour IOP measurements for individual patients were performed by multiple nurses. Regarding patient perceptions, 95.8% considered 24-hour IOP monitoring important, yet 52.9% expressed reluctance to undergo the repeated procedure, citing hospitalization inconvenience (80%), sleep disruption (28.9%), concerns about measurement accuracy (4.4%), and cost (4.4%). Although over half of the surveyed hospitals had implemented 24-hour IOP monitoring, overall clinical utilization remained suboptimal, with highly heterogeneous local protocols and considerable patient reluctance toward the current inpatient-based, nurse-dependent monitoring paradigm. Standardized implementation of national guidelines, enhanced patient education, and development of patient-centric, wearable IOP monitoring technologies are essential to optimize accessibility and support glaucoma management.
- 1 February 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-11
Open AccessImplementation and Clinical Application of 24-Hour Intraocular Pressure Monitoring in China: A Nationwide Survey
To evaluate the nationwide implementation and clinical application of 24-hour intraocular pressure (IOP) monitoring in China. A nationwide descriptive cross-sectional study was conducted from September 2024 to March 2025. Two structured questionnaires were distributed to 467 hospitals across China (400 valid responses) and 170 patients recruited from our institution who were undergoing 24-hour IOP monitoring for the first time. Collected data included implementation rates, tonometer types, measurement protocols, examiner consistency, and patient-reported perceptions. Among the 400 responding hospitals, 261 (65.3%) had implemented 24-hour IOP monitoring; however, 85.1% managed fewer than 20 patients per month. The most common measurement frequencies within a 24-hour period were 12 (37.2%), 6 (32.6%), and 7 times (27.2%), respectively. Non-contact tonometer (NCT) was the predominant device for both daytime (67.8%) and nighttime (64.6%) measurements. Among the 175 hospitals performing nocturnal measurements, only 7.4% employed supine positioning. In 65.5% of institutions, 24-hour IOP measurements for individual patients were performed by multiple nurses. Regarding patient perceptions, 95.8% considered 24-hour IOP monitoring important, yet 52.9% expressed reluctance to undergo the repeated procedure, citing hospitalization inconvenience (80%), sleep disruption (28.9%), concerns about measurement accuracy (4.4%), and cost (4.4%). Although over half of the surveyed hospitals had implemented 24-hour IOP monitoring, overall clinical utilization remained suboptimal, with highly heterogeneous local protocols and considerable patient reluctance toward the current inpatient-based, nurse-dependent monitoring paradigm. Standardized implementation of national guidelines, enhanced patient education, and development of patient-centric, wearable IOP monitoring technologies are essential to optimize accessibility and support glaucoma management.
- Top Cited PapersOpen Access
- 12 March 2025
- Published by Elsevier in Advances in Ophthalmology Practice and Research
- Vol. 5 (2) , 142-148
The impact of intraocular pressure fluctuations on the progression of glaucoma and associated factors
- 12 March 2025
- Published by Elsevier in Advances in Ophthalmology Practice and Research
- Vol. 5 (2) , 142-148
Top Cited PapersOpen AccessThe impact of intraocular pressure fluctuations on the progression of glaucoma and associated factors
- Open Access
- 27 February 2025
- Published by Springer Nature in BMC Ophthalmology
- Vol. 25 (1) , 1-9
Management of fracture and displacement of a previously successful bilateral transconjunctival ab-externo XEN gel stent: a case report
The XEN45 Gel Stent (XGS) is an innovative, minimally invasive glaucoma surgery device, which is typically inserted via an ab-interno method, avoiding conjunctival dissection. With increasing experience, some surgeons have advocated for a transconjunctival ab-externo approach, with or without conjunctival dissection, for the delivery of XGS. A 33-year-old male patient with a history of primary open-angle glaucoma diagnosed three years ago presented to the clinic with the complaint of visual field loss. This case report presents the initial implantation of XGS in both glaucoma eyes, using the transconjunctival ab-externo technique without conjunctival dissection. However, subsequent follow-up revealed that in the left eye, the XGS had been fractured as a result of external force. Meanwhile, in the right eye, the displacement of the XGS was attributed to the surgical needlework. To facilitate re-implantation, the transconjunctival ab-externo approach with conjunctival dissection was employed to enhance the securement of the XGS. The case highlights that external force and needling can cause XGS fracture and displacement. To reduce this risk, employing a transconjunctival ab-externo approach with conjunctival dissection and securing the XGS with sutures was found to decrease complications, indicating a more effective surgical strategy for XGS implantation.
- 27 February 2025
- Published by Springer Nature in BMC Ophthalmology
- Vol. 25 (1) , 1-9
Open AccessManagement of fracture and displacement of a previously successful bilateral transconjunctival ab-externo XEN gel stent: a case report
The XEN45 Gel Stent (XGS) is an innovative, minimally invasive glaucoma surgery device, which is typically inserted via an ab-interno method, avoiding conjunctival dissection. With increasing experience, some surgeons have advocated for a transconjunctival ab-externo approach, with or without conjunctival dissection, for the delivery of XGS. A 33-year-old male patient with a history of primary open-angle glaucoma diagnosed three years ago presented to the clinic with the complaint of visual field loss. This case report presents the initial implantation of XGS in both glaucoma eyes, using the transconjunctival ab-externo technique without conjunctival dissection. However, subsequent follow-up revealed that in the left eye, the XGS had been fractured as a result of external force. Meanwhile, in the right eye, the displacement of the XGS was attributed to the surgical needlework. To facilitate re-implantation, the transconjunctival ab-externo approach with conjunctival dissection was employed to enhance the securement of the XGS. The case highlights that external force and needling can cause XGS fracture and displacement. To reduce this risk, employing a transconjunctival ab-externo approach with conjunctival dissection and securing the XGS with sutures was found to decrease complications, indicating a more effective surgical strategy for XGS implantation.
- Open Access
- 12 November 2024
- Published by Elsevier in Advances in Ophthalmology Practice and Research
- Vol. 5 (2) , 124-134
Nano-based drug delivery systems for the treatment of non-infectious uveitis
- 12 November 2024
- Published by Elsevier in Advances in Ophthalmology Practice and Research
- Vol. 5 (2) , 124-134
Open AccessNano-based drug delivery systems for the treatment of non-infectious uveitis
- 1 July 2024
- Published by Springer Nature in International Ophthalmology
- Vol. 44 (1) , 299
The spike of acute angle closure after the epidemic downgrade of COVID-19 management: a hospital-based comparative study from China
Purpose To analyse and compare the clinical characteristics and treatment outcomes of patients with acute angle closure (AAC) who presented before the COVID-19 pandemic, during the COVID-19 management and after their downgrading. Methods Consecutive AAC patients were recruited from our hospital and divided into three groups: those treated before the COVID-19 pandemic (Group1), during the COVID-19 management (Group2) and after the management downgrade (Group3). The demographic variables, clinical characteristics, treatment methods and therapeutic outcomes of the groups were compared. Results When compared to Groups1 and 2, Group3 showed a significantly higher incidence of AAC (0.27%, P < 0.001), a longer time from symptoms to treatment (TST; 160.88 +/- 137.05 h, P = 0.031) and worse uncorrected visual acuity (P = 0.009) at presentation. In Group3, 68.9% had a history of COVID-19 and 28.5% developed ocular symptoms of AAC after taking medication for COVID-19 symptoms. The average time from the onset of COVID-19 to the appearance of eye symptoms was 3.21 +/- 4.00 days. Conclusions The COVID-19 has had a multifaceted impact on the incidence of AAC. Therefore, it is crucial to strengthen health education on glaucoma, especially AAC. The prevention and timely treatment of AAC should be emphasised to combat global blindness.
- 1 July 2024
- Published by Springer Nature in International Ophthalmology
- Vol. 44 (1) , 299
The spike of acute angle closure after the epidemic downgrade of COVID-19 management: a hospital-based comparative study from China
Purpose To analyse and compare the clinical characteristics and treatment outcomes of patients with acute angle closure (AAC) who presented before the COVID-19 pandemic, during the COVID-19 management and after their downgrading. Methods Consecutive AAC patients were recruited from our hospital and divided into three groups: those treated before the COVID-19 pandemic (Group1), during the COVID-19 management (Group2) and after the management downgrade (Group3). The demographic variables, clinical characteristics, treatment methods and therapeutic outcomes of the groups were compared. Results When compared to Groups1 and 2, Group3 showed a significantly higher incidence of AAC (0.27%, P < 0.001), a longer time from symptoms to treatment (TST; 160.88 +/- 137.05 h, P = 0.031) and worse uncorrected visual acuity (P = 0.009) at presentation. In Group3, 68.9% had a history of COVID-19 and 28.5% developed ocular symptoms of AAC after taking medication for COVID-19 symptoms. The average time from the onset of COVID-19 to the appearance of eye symptoms was 3.21 +/- 4.00 days. Conclusions The COVID-19 has had a multifaceted impact on the incidence of AAC. Therefore, it is crucial to strengthen health education on glaucoma, especially AAC. The prevention and timely treatment of AAC should be emphasised to combat global blindness.
- Open Access
- 11 May 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 175, 116711
NADPH and NAC synergistically inhibits chronic ocular hypertension-induced neurodegeneration and neuroinflammation through regulating p38/MAPK pathway and peroxidation
- 11 May 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 175, 116711
Open AccessNADPH and NAC synergistically inhibits chronic ocular hypertension-induced neurodegeneration and neuroinflammation through regulating p38/MAPK pathway and peroxidation
- Open Access
- 1 November 2023
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 64 (14) , 20
Comparison Between Two Types of Viral-Induced Anterior Uveitis In Vitro and In Vivo: A Stronger Response in Herpes Simplex Virus Type 1 Than in Murine Cytomegalovirus
Purpose: To observe the similarities and differences between herpes simplex virus type 1 (HSV-1) and murine cytomegalovirus (MCMV)–induced viral anterior uveitis (VAU), both in vitro and in vivo. Methods: Primary rat trabecular meshwork cells (RTMCs) were infected by HSV-1 or MCMV to clarify the pattern of virus replication and the effect on cells. In vivo, intracameral injection of HSV-1 or MCMV was performed to establish the VAU rat models. The clinical manifestation, intraocular pressure (IOP), histological characteristics, ultrastructural changes, and the expression of inflammatory cytokines in the anterior segment were observed and compared between these two types of VAU models. Results: Both viruses could infect the RTMCs but HSV-1 exhibited an earlier and greater cytopathic effect in vitro. In vivo, both VAU rats showed typical acute VAU signs, and the IOP elevation seemed to be correlated with the inflammatory progression. Histopathological findings and ultrastructural changes revealed tissue damage and cell infiltration in the anterior chamber angle. In both models, similar proinflammatory cytokines were upregulated. HSV-1 and MCMV viral particles were identified under transmission electron microscopy. Conclusions: HSV-1 and MCMV infection share certain similarities but have significant differences both in vitro and in vivo. HSV-1 usually has a stronger anterior segment inflammation with a longer duration compared with MCMV in VAU models. Our results provided a valuable animal model for investigating pathogenesis and exploring therapeutic strategies for clinical VAU.
- 1 November 2023
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 64 (14) , 20
Open AccessComparison Between Two Types of Viral-Induced Anterior Uveitis In Vitro and In Vivo: A Stronger Response in Herpes Simplex Virus Type 1 Than in Murine Cytomegalovirus
Purpose: To observe the similarities and differences between herpes simplex virus type 1 (HSV-1) and murine cytomegalovirus (MCMV)–induced viral anterior uveitis (VAU), both in vitro and in vivo. Methods: Primary rat trabecular meshwork cells (RTMCs) were infected by HSV-1 or MCMV to clarify the pattern of virus replication and the effect on cells. In vivo, intracameral injection of HSV-1 or MCMV was performed to establish the VAU rat models. The clinical manifestation, intraocular pressure (IOP), histological characteristics, ultrastructural changes, and the expression of inflammatory cytokines in the anterior segment were observed and compared between these two types of VAU models. Results: Both viruses could infect the RTMCs but HSV-1 exhibited an earlier and greater cytopathic effect in vitro. In vivo, both VAU rats showed typical acute VAU signs, and the IOP elevation seemed to be correlated with the inflammatory progression. Histopathological findings and ultrastructural changes revealed tissue damage and cell infiltration in the anterior chamber angle. In both models, similar proinflammatory cytokines were upregulated. HSV-1 and MCMV viral particles were identified under transmission electron microscopy. Conclusions: HSV-1 and MCMV infection share certain similarities but have significant differences both in vitro and in vivo. HSV-1 usually has a stronger anterior segment inflammation with a longer duration compared with MCMV in VAU models. Our results provided a valuable animal model for investigating pathogenesis and exploring therapeutic strategies for clinical VAU.
- Open Access
- 22 September 2023
- Published by Elsevier in Advances in Ophthalmology Practice and Research
- Vol. 3 (4) , 171-179
Development and material characteristics of glaucoma surgical implants
- 22 September 2023
- Published by Elsevier in Advances in Ophthalmology Practice and Research
- Vol. 3 (4) , 171-179
Open AccessDevelopment and material characteristics of glaucoma surgical implants
- Open Access
- 19 September 2023
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (9) , 1-13
Inhibition of cGAS–STING pathway alleviates neuroinflammation-induced retinal ganglion cell death after ischemia/reperfusion injury
Acute glaucoma is a vision-threatening disease characterized by a sudden elevation in intraocular pressure (IOP), followed by retinal ganglion cell (RGC) death. Cytosolic double-stranded DNA (dsDNA)—a damage-associated molecular pattern (DAMP) that triggers inflammation and immune responses—has been implicated in the pathogenesis of IOP-induced RGC death, but the underlying mechanism is not entirely clear. In this study, we investigated the effect of the inflammatory cascade on dsDNA recognition and examined the neuroprotective effect of the cyclic GMP-AMP (cGAMP) synthase (cGAS) antagonist A151 on a retinal ischemia/reperfusion (RIR) mouse model. Our findings reveal a novel mechanism of microglia-induced neuroinflammation-mediated RGC death associated with glaucomatous vision loss. We found that RIR injury facilitated the release of dsDNA, which initiated inflammatory responses by activating cGAS–stimulator of interferon genes (STING) pathway. Correspondingly, elevated expressions of cGAS and STING were found in retinal samples from human glaucoma donors. Furthermore, we found that deletion or inhibition of cGAS or STING in microglia transfected with poly(dA:dT) specifically decreased microglia activation and inflammation response. We also observed that A151 treatment promoted poly(dA:dT)--stimulated changes in polarization from the M1 to the M2 phenotype in microglia. Subsequently, A151 administered to mice effectively inhibited the cGAS–STING pathway, absent in melanoma 2 (AIM2) inflammasome and pyroptosis-related molecules. Furthermore, A151 administration significantly reduced neuroinflammation, ameliorated RGC death and RGC-related reductions in visual function. These findings provide a unique perspective on glaucomatous neuropathogenesis and suggest cGAS as an underlying target of retinal inflammation to provide a potential therapeutic for acute glaucoma.
- 19 September 2023
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (9) , 1-13
Open AccessInhibition of cGAS–STING pathway alleviates neuroinflammation-induced retinal ganglion cell death after ischemia/reperfusion injury
Acute glaucoma is a vision-threatening disease characterized by a sudden elevation in intraocular pressure (IOP), followed by retinal ganglion cell (RGC) death. Cytosolic double-stranded DNA (dsDNA)—a damage-associated molecular pattern (DAMP) that triggers inflammation and immune responses—has been implicated in the pathogenesis of IOP-induced RGC death, but the underlying mechanism is not entirely clear. In this study, we investigated the effect of the inflammatory cascade on dsDNA recognition and examined the neuroprotective effect of the cyclic GMP-AMP (cGAMP) synthase (cGAS) antagonist A151 on a retinal ischemia/reperfusion (RIR) mouse model. Our findings reveal a novel mechanism of microglia-induced neuroinflammation-mediated RGC death associated with glaucomatous vision loss. We found that RIR injury facilitated the release of dsDNA, which initiated inflammatory responses by activating cGAS–stimulator of interferon genes (STING) pathway. Correspondingly, elevated expressions of cGAS and STING were found in retinal samples from human glaucoma donors. Furthermore, we found that deletion or inhibition of cGAS or STING in microglia transfected with poly(dA:dT) specifically decreased microglia activation and inflammation response. We also observed that A151 treatment promoted poly(dA:dT)--stimulated changes in polarization from the M1 to the M2 phenotype in microglia. Subsequently, A151 administered to mice effectively inhibited the cGAS–STING pathway, absent in melanoma 2 (AIM2) inflammasome and pyroptosis-related molecules. Furthermore, A151 administration significantly reduced neuroinflammation, ameliorated RGC death and RGC-related reductions in visual function. These findings provide a unique perspective on glaucomatous neuropathogenesis and suggest cGAS as an underlying target of retinal inflammation to provide a potential therapeutic for acute glaucoma.